Acute attacks of hereditary angioedema (DBCOND0024027)

Identifiers

Synonyms

Acute attacks Hereditary angioedema / Hereditary angioedema attack / Acute attack of hereditary angioedema / Hereditary angioedema C1 inhibitor deficiency / Hereditary angioedema / Hereditary angioneurotic edema (disorder) / Angioedemas, Hereditary / C1 esterase inhibitor deficiency

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Berotralstat	An inhibitor of plasma kallikrein used for prophylaxis of angioedema attacks in patients with hereditary angioedema.	Cytochrome P450 2D6enzyme Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Plasma kallikreintarget
Conestat alfa	A recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.	Complement C1r subcomponenttarget Complement C1s subcomponenttarget Plasma kallikreintarget Coagulation factor XIItarget Prothrombintarget Coagulation factor XItarget Tissue-type plasminogen activatortarget
Ecallantide	A kallikrein inhibitor used to prevent and treat acute attacks caused by Hereditary Angioedema (HAE).	Plasma kallikreintarget
Human C1-esterase inhibitor	A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.	Complement C1r subcomponenttarget Complement C1s subcomponenttarget Plasma kallikreintarget Coagulation factor XIItarget Prothrombintarget Coagulation factor XItarget Tissue-type plasminogen activatortarget
Icatibant	A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).	B2 bradykinin receptortarget Aminopeptidase Ntarget
Lanadelumab	A monoclonal antibody targeted against kallikrein which is used to treat attacks of hereditary angioedema.	Plasma kallikreintarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06343779	Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema	No drug interventions	treatment	3	recruiting
NCT05396105	Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema	Deucrictibant	treatment	2 / 3	enrolling_by_invitation
NCT05047185	Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II	Deucrictibant	prevention	2	active_not_recruiting
NCT04618211	Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema	Deucrictibant	treatment	2	completed